OxTalks will soon be transitioning to Oxford Events (full details are available on the Staff Gateway). A two-week publishing freeze is expected to start before the end of Hilary Term to allow all future events to be migrated to the new platform. During this period, you will not be able to submit or edit events on OxTalks. The exact freeze dates will be confirmed on the Staff Gateway and via email to identified OxTalks users.
If you have any questions, please contact halo@digital.ox.ac.uk
The past two decades have witnessed a revolution in rheumatoid arthritis (RA) outcomes, with remission now a realistic and achievable target for many patients. However, this heralds a new dilemma increasingly encountered in routine clinical practice: how best to manage expensive and potentially toxic immunosuppressive therapy in such individuals?
I will present our clinical trial data to support a composite biomarker capable of predicting drug-free remission in established RA. The concept of drug-free remission will also be explored from a patient perspective, together with ongoing and future avenues of research to better understand the pathoimmunological processes underpinning RA flare.
